Health · Pharma & Biotech · 1 day ago
FDA approves monthly injectable olanzapine for adults with schizophrenia
The FDA has approved Weltruza, a once-monthly injection of olanzapine for adults with schizophrenia.
The medicine is given under the skin.
Olanzapine has been used for decades in pill form.
The approval adds an injectable option for adults with schizophrenia.
Teva Pharmaceuticals announced the approval.
The available information does not say when the treatment will become available.
The FDA approved a once-monthly injectable form of olanzapine for adults with schizophrenia.
The formulation is given by subcutaneous injection.
Teva Pharmaceuticals announced the approval on Friday.
The product is called Weltruza.
- Who
- The FDA approved the formulation; Teva Pharmaceuticals announced the approval.
- What
- Approval was granted for once-monthly subcutaneous olanzapine, marketed as Weltruza, for adults with schizophrenia.
- When
- Friday; the article was published on October 9, 2026.
- Where
- Not stated.
- Why
- It is for treating schizophrenia in adults.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Drug
- Olanzapine
- Brand name
- Weltruza
- Dosing schedule
- Once monthly
- Administration
- Subcutaneous injection
- Indication
- Schizophrenia in adults
- Announcement
- Teva Pharmaceuticals, Friday
Sources
Related news
Baby Sleep Gripe Water Recalled After Alcohol Found in Testing
FDA Warns Amazon Over Unapproved Herpes Treatments
Possible Wrong Dose Raises Questions for PDE9 Drug Trials in Heart Failure
Experimental eye drops improve vision in a small study of a rare eye disease
Brazil suspends Peptistrong supplement and orders all batches recalled
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Taboos limit sales of weight-loss drugs in India despite obesity rates
Roche reports year-long results for eye drug Vamikibart
Daily painkiller use can hide the cause of ongoing pain
Swiss oncologist warns US drug pricing pressure could delay cancer therapies
